FDA Re-Establishes Compounding Advisory Committee
The Drug Quality and Security Act requires the FDA to reconvene the Pharmacy Compounding Advisory Committee, a group previously established in 1997 by the enactment of FDAMA but essentially disbanded by the FDA in 2005. The Committee will have responsibilities for reviewing submissions for inclusion of APIs on various permitted lists as well as making recommendations for medications which should not be compounded.
The Committee will be composed of a core of 12 voting members including the Chair. Members and the Chair are selected by the Commissioner or designee from among authorities knowledgeable in the fields of pharmaceutical compounding, pharmaceutical manufacturing, pharmacy, medicine, and related specialties. Membership also includes representatives from the National Association of Boards of Pharmacy and the United States Pharmacopoeia, and representatives of patient and public health advocacy organizations. Members will be invited to serve for overlapping terms of up to 4 years. Almost all non-Federal members of this committee will serve as special Government employees.
IACP will be submitting nominations to this Committee in accordance with the series of instructions published in the Federal Register. If you would like to have the Academy submit your name, please submit your complete resume or CV to us along with a specific statement that you would like to serve on this Committee to email@example.com no later than Friday, 24 January 2014.